The effect of methotrexate on improving serological abnormalities of patients with systemic lupus erythematosus

Modern Rheumatology

Volumn 23, Issue 4, 2013, Pages 659-666

  Miyawaki, Shoji ^a   Nishiyama, Susumu ^a   Aita, Tetsushi ^a   Yoshinaga, Yasuhiko ^a  

^a University of Tokyo   (Japan)

Author keywords

Anti dsDNA antibody; Complement; Methotrexate; SLEDAI; Systemic lupus erythematosus

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIVER ENZYME; METHOTREXATE; PREDNISOLONE;

ADULT; ARTICLE; BRONCHITIS; CLINICAL ARTICLE; CLINICAL FEATURE; COMPLEMENT BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; ERYTHROCYTE; FATIGUE; FEMALE; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOASSAY; IMMUNOGLOBULIN BLOOD LEVEL; LABORATORY TEST; MEAN CORPUSCULAR VOLUME; METABOLIC DISORDER; MOUTH ULCER; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROLOGY; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; TASTE DISORDER; TURBIDIMETRY;

EID: 84880793351     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-012-0707-9     Document Type: Article

References (24)

1. Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA. The pharmacology and clinical use of methotrexate. N Engl J Med. 1983;309:1094-104.
2. Braun J, Rau R. An update on methotrexate. Curr Opin Rheum. 2009;21:216-23.
3. Rothenberg RJ, Graziano FM, Grandone JT, Goldenberg JW, Bjamason DF, Finesilver AG. The use of methotrexate in steroid-resistant systemic lupus erythematosus. Arthritis Rheum. 1988;31:612-5.
4. Wilson K, Abeles M. A 2 year, open ended trial of methotrexate in systemic lupus erythematosus. J Rheumatol. 1994;21:1674-7.
5. Wise CM, Vuyyuru S, Roberts WN. Methotrexate in nonrenal lupus and undifferentiated connective tissue disease - a review of 36 patients. J Rheumatol. 1996;23:1005-10.
6. Rahman P, Humphrey-Murto S, Gladman DD, Urowitz MB. Efficacy and tolerability of methotrexate in antimalarial resistant lupus arthritis. J Rheumatol. 1998;25:243-6.
7. Carneiro JRM, Sato EL. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol. 1999;26:1275-9.
8. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum. 1992;35:630-40.
9. Gansauge S, Breitbart A, Rinaldi N, Schwarz-Eywill M. Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease). Ann Rheum Dis. 1997;56:382-5.
10. Fortin PR, Abrahamowicz M, Ferland D, Lacaille D, Smith CD, Zummer M. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blinded, randomized, placebo-controlled trial. Arthritis Rheum. 2008;59:1796-804.
11. Schur PH, Swanson J. Immunologic factors and clinical activity in systemic erythematosus. N Engl J Med. 1968;278:533-8.
12. Lloyd W, Schur PH. Immune complexes, complement, and anti-dsDNA in exacerbations of systemic lupus erythematosus (SLE). Medicine. 1981;60:208-17.
13. Swaak AJG, Gorenwold J, Bronsveld W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis. 1986;45:359-66.
14. Sullivan KE, Wisnieski JJ, Winkelstein JA, Louie J, Sachs E, Choi R, et al. Serum complement determinations in patients with quiescent systemic lupus erythematosus. J Rheumatol. 1996;23:2063-7.
15. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of SLE. Arthritis Rheum. 1983;25:1271-7.
16. Yamanaka H, Inoue E, Tanaka E, Nakajima A, Taniguchi A, Terai C, et al. Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients: evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observation cohort (IORRA). Mod Rheumatol. 2007;17:98-105.
17. Glantz SA. Primers of biostatistics. 5th ed. NY: McGraw-Hill, Inc. Health Professions Division; 2002. p. 89-90.
18. Ravelli A, Ballardini G, Viola S, Villa I, Ruperto N, Martini A. Methotrexate therapy in refractory pediatric onset systemic lupus erythematosus. J Rheumatol. 1998;25:572-5.
19. Galarza D, Esquivel J, Villarreal M, de la Garza N, Garza M. Methotrexate in lupus nephritis: an uncontrolled study, preliminary results. Arthritis Rheum. 1992;34;187 (abstract D140).
20. Abud-Mendoza C, Sturbaum AK, Vazquez-Compean P, Gonzalez-Amaro R. Methotrexate therapy in childhood systemic lupus erythematosus. J Rheumatol. 1993;20:731-3.
21. Smeenk RJ, van den Brink HG, Brinkman K, Termaat RM, Berden JH, Swaak AJ. Anti-dsDNA: choice of assay in relation to clinical value. Rheumatol Int. 1991;11:101-7.
22. Hahn BH, Tsao BP. Antibodies to DNA. In: Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 425-45.
23. Neogi T, Gladman DD, Ibañez D, Urowitz MB. Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent. J Rheumatol. 2006;33:1785-8.
24. Steinman AJ, Gladman DD, Ibañez D, Urowitz MB. Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome. J Rheumatol. 2010;37:1822-7.